Neophyr (Nitric Oxide)

Neophyr, containing inhaled nitric oxide, is used in clinical settings to manage conditions characterized by elevated pulmonary vascular resistance.

• Persistent Pulmonary Hypertension of the Newborn (PPHN): reduces pulmonary arterial pressure, enhancing oxygen delivery and supporting transition to independent breathing.
• Acute Respiratory Distress Syndrome (ARDS): improves ventilation‑perfusion matching by selectively dilating well‑ventilated lung regions, potentially aiding oxygenation.
• Chronic Pulmonary Hypertension in adults: lowers pulmonary arterial pressure, alleviating dyspnea and improving exercise tolerance.
• Pulmonary hypertension associated with congenital heart disease: provides selective pulmonary vasodilation to improve hemodynamics.

• Inhaled nitric oxide diffuses across the alveolar‑capillary membrane into pulmonary vascular smooth muscle cells, where it binds to soluble guanylate cyclase. This activation raises intracellular cyclic guanosine monophosphate (cGMP) levels, causing relaxation of smooth muscle fibers and selective dilation of pulmonary vessels. The effect is localized to ventilated lung regions, reducing pulmonary arterial pressure without systemic vasodilation. The increased cGMP also inhibits calcium influx, further supporting vasorelaxation.

Inhalation of nitric oxide may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Methemoglobinemia: elevated methemoglobin levels causing reduced oxygen-carrying capacity.
• Nitrogen dioxide formation: irritant gas generated from NO oxidation, may cause airway irritation.
• Cough: mild respiratory irritation leading to coughing episodes.
• Headache: transient headache due to vasodilatory effect.
• Dizziness: mild light‑headedness associated with systemic vasodilatory effect.
• Nausea: occasional nausea reported during therapy.

Serious or Rare Side Effects

• Rebound pulmonary hypertension: sudden rise in pulmonary pressure after abrupt discontinuation.
• Systemic hypotension: unexpected drop in systemic blood pressure in susceptible patients.
• Bleeding complications: increased risk of hemorrhage due to platelet inhibition.
• Renal impairment: potential worsening of renal function in susceptible patients.

When using inhaled nitric oxide, specific precautions should be observed to ensure patient safety and product integrity.

• Methemoglobin monitoring: regularly assess methemoglobin levels to detect early elevation.
• NO2 concentration control: maintain nitrogen dioxide below recommended limits by adjusting flow rates.
• Anemia caution: avoid use in patients with severe anemia due to reduced oxygen delivery.
• Renal function assessment: evaluate renal status as nitric oxide may affect renal perfusion.
• Discontinuation protocol: taper or monitor closely when stopping therapy to prevent rebound pulmonary hypertension.
• Store at ambient temperature: keep container sealed, protect from moisture and direct sunlight.

Nitric oxide inhalation can interact with certain medications and gases, influencing its efficacy and safety profile.

Major Interactions (Avoid)

• Methylene blue: can increase methemoglobin formation, counteracting nitric oxide therapy.
• Phosphodiesterase‑5 inhibitors (e.g., sildenafil): additive pulmonary vasodilation may cause excessive hypotension.
• High inspired oxygen concentrations: promote nitrogen dioxide generation, increasing airway irritation.

Moderate Interactions (Monitor Closely)

• Inhaled anesthetics (e.g., sevoflurane): may potentiate vasodilatory effects.
• Anticoagulants (e.g., heparin): potential for increased bleeding risk.
• Beta‑blockers: may blunt compensatory cardiovascular responses.